High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma

Anticancer Research

Volumn 28, Issue 5 A, 2008, Pages 2715-2719

  Honkavuori, Maria ^a   Talvensaari Mattila, Anne ^a   Puistola, Ulla ^a   Turpeenniemi Hujanen, Taina ^a   Santala, Markku ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

Endometrial cancer; MMP 2; MMP 9; Prognosis; TIMP 1; TIMP 2

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; BLOOD LEVEL; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 55749084920     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N and Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7: 3113-3119, 2001.
2. Stetler-Stevenson WG, Hewitt R and Corcoran M: Matrix metalloproteinases and invasion: from correlation and causality to the clinic. Cancer Biol 7: 147-154, 1996.
3. Curran S and Murray GI: Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189: 300-308, 1999.
4. Turpeenniemi-Hujanen T: Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87: 287-297, 2005.
5. Chambers AF and Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260-1270, 1997.
6. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000.
7. Pilka R, Norata GD, Domanski H, Andersson C, Hansson S, Eriksson P and Casslén B: Matrix metalloproteinase-26 (Matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancer. Gynecol Oncol 95: 661-670, 2004.
8. Lambert E, Dassé E, Haye B and Petitfrère E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol 49: 187-198, 2004.
9. Gomez DE, Alonso DF, Yoshiji H and Thorgeirsson UP: Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74: 111-122, 1997.
10. Stetler-Stevenson WG, Krutzsch HC and Liotta LA: Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 264: 17374-17378, 1989.
11. Rauvala M, Puistola U and Turpeenniemi-Hujanen T: Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol 99: 656-663, 2005.
12. Ruokolainen H, Pääkkö P and Turpeenniemi-Hujanen T: Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma - tissue immuno-reactivity predicts aggressive clinical course. Mod Pathol 19: 208-217, 2006.
13. Ylisirniö S, Höyhtyä M and Turpeenniemi-Hujanen T: Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1 and -2 in lung cancer - TIMP-1 as a prognostic marker. Anticancer Res 20: 1311-1316, 2000.
14. Talvensaari-Mattila A and Turpeenniemi-Hujanen T: High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma. Breast Cancer Res Treat 89: 29-34, 2005.
15. Ruokolainen H, Pääkkö P and Turpeenniemi-Hujanen T: Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein. Clin Cancer Res 11: 3257-3264, 2005.
16. Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W and Brunner N: High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 6: 4292-4299, 2000.
17. Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, Taraboletti G, Labianca R, Belotti D and Giavazzi R: Expression levels of vascular endothelial growth factor, matrix metallo-proteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 39: 1948-1956, 2003.
18. Kuvaja P, Talvensaari-Mattila A, Pääkkö P and Turpeenniemi-Hujanen T: The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1) but not for TIMP-2 protein is associated with a favourable prognosis in aggressive breast carcinoma. Oncology 68: 196-203, 2005.
19. Jung K, Lein M, Laube C and Lichtinghagen R: Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 314: 241-244, 2001.
20. Kuvaja P, Talvensaari-Mattila A and Turpeenniemi-Hujanen T: The sample type used affects the levels of gelatinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in circulating blood of healthy controls and breast cancer patients. Biomarker Insights 2: 117-127, 2007.
21. Vasala K and Turpeenniemi-Hujanen T: Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer. Clin Biochem 40: 640-644, 2007.
22. Kuvaja P, Talvensaari-Mattila A, Pääkkö P and Turpeenniemi-Hujanen T: Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma. Hum Pathol 37: 1316-1323, 2006.
23. Hoikkala S, Pääkkö P, Soini Y, Mäkitaro R, Kinnula V and Turpeenniemi-Hujanen T: Tissue MMP-2 and MMP-9 are better prognostic factors than serum MMP-2/TIMP-2 complex or TIMP-1 in stage I-III lung carcinoma. Cancer Lett 236: 125-132, 2006.
24. Talvensaari-Mattila A, Pääkkö P and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 89: 1270-1275, 2003.
25. Leppä S, Saarto T, Vehmanen L, Blomqvist C and Elomaa I: A high serum matrix metalloproteinase-2 level is assosiated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 10: 1057-1063, 2004.
26. Oberg A, Höyhtyä M, Tavelin B, Stenling R and Lindmark G: Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 20: 1085-1091, 2000.
27. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, de e Nictolis M, Garbisa S, Masiero L, Romanini C and Graziella B: Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystadenocarcinomas: clinical and prognostic implications. Anticancer Res 15: 2799-2804, 1995.
28. Adamiak A, Postawski K, Semczuk A, Rechberger T and Jakowicki JA: Prognostic value of serum MMP-2 level in uterine cancer-affected women. Ginekol Pol 71: 1198-1201, 2000 (In Polish).